Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
/ 45 items
#PFE↓
Patient Death in Pfizer's Hympavzi Trial Raises Safety Questions for Hemophilia Treatment
Pfizer investigates death of hemophilia patient in Hympavzi trial after thrombotic stroke. Company says no expected safety impact for approved use.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Pfizer Forecasts Flat Growth in 2026 Amid Pipeline Refresh
Pfizer projects $59.5-62.5B revenue for 2026 with minimal growth as it invests in obesity drugs and cuts costs while COVID sales decline and key patents expire.
Adaptive Biotechnologies Partners with Pfizer on Immune Disease Research
Adaptive Biotechnologies signs two deals with Pfizer worth up to $890M to discover rheumatoid arthritis treatments and share immune system data for AI-powered drug development.
FDA Memo on Vaccine Deaths Sends Moderna, Novavax Stocks Tumbling
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.